Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT162b7
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
BNT162b7 is an investigational mRNA-based vaccine candidate developed by BioNTech and Pfizer for the prevention of COVID-19. It is part of a next-generation series of SARS-CoV-2 vaccine candidates (including BNT162b4, BNT162b5, and BNT162b6) designed to evaluate different mRNA constructs and formulations to enhance the breadth and durability of the immune response. BNT162b7 has been studied in clinical trials, such as NCT05477368, in both monovalent (targeting the Omicron BA.4/BA.5 variant) and bivalent (targeting the original SARS-CoV-2 strain and Omicron BA.4/BA.5) forms. The vaccine utilizes lipid nanoparticle (LNP) technology to deliver mRNA encoding the viral spike protein, thereby inducing neutralizing antibodies and T-cell responses in vaccine-experienced individuals.
- Other names
- BNT162b7 BivalentBNT-162b7 BivalentBNT 162b7 BivalentBNT162b7 MonovalentBNT-162b7 MonovalentBNT 162b7 Monovalent
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on BNT162b7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT162b7.